Specializing In
- Advanced Solid Tumors treated with Cellular Therapy
- Cellular Immunotherapy
- Cellular Therapy
- Immunotherapy
- Melanoma Skin Cancer
- Nonmelanoma Skin Cancer
- Skin Cancer
- Targeted Therapy
- Tumor-Infiltrating Lymphocyte Therapy
Biography
Dr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2018)
- Fellowship: Memorial Sloan Kettering Cancer Center (2019) NY
- Board Certification: American Board of Internal Medicine, Internal Medicine (2016)
-
- Residency: Massachusetts General Hospital Internal Medicine Residency (2016) MA
- Medical Education: Duke University School of Medicine (2013) NC
Honors & Awards
- Innovation of Care Award, Stanford Healthcare (2025)
-
Administrative Appointments
- Co-Director, Pigmented Lesion & Melanoma Clinic, School of Medicine (2023 - Present)
- Director, Advanced Melanoma Program, School of Medicine (2023 - Present)
- Director, Solid Tumor Cell Therapy, School of Medicine (2023 - Present)
-
- Leader, Melanoma & Cutaneous Oncology Clinical Research Group, School of Medicine (2023 - Present)
- Mark and Mary Stevens Endowed Faculty Scholar, School of Medicine (2023 - Present)
- Medical Director (Cancer Center Program Physician Leader), Melanoma Oncology, School of Medicine (2023 - Present)
Publications
-
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon, A. C., Burton, L. B., Chwalisz, B. K., Hillis, J., Schaller, T. H., Amato, A. A., … Reynolds, K. L. (2021). Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. Journal for Immunotherapy of Cancer, 9(7). -
Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus.
Costa, B. A., Zibara, V., Singh, V., Hamid, O., Gandhi, S., Moy, A. P., & Betof Warner, A. S. (2022). Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus. Frontiers in Medicine, 9, 1086473. -
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
Betof Warner, A., Corrie, P. G., & Hamid, O. (2022). Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
-
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Loo, K., Smithy, J. W., Postow, M. A., & Betof Warner, A. (2021). Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Frontiers in Immunology, 12, 810388. -
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto, P. A., Warner, A. B., Blank, C., Caracò, C., Demaria, S., Gershenwald, J. E., … Puzanov, I. (2022). The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. Journal of Translational Medicine, 20(1), 200. -
The future of cancer immunotherapy: microenvironment-targeting combinations.
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020). The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research, 30(6), 507–519. -
Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome.
Warner, A. B., & McQuade, J. L. (2019). Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. Current Oncology Reports, 21(8), 72. -
Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?
Zhang, X., Ashcraft, K. A., Betof Warner, A., Nair, S. K., & Dewhirst, M. W. (2019). Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? Cancer Research, 79(10), 2447–2456. -
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner, A. B., & Postow, M. A. (2018). Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma? Oncology (Williston Park, N.Y.), 32(5), 228–34. -
Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure.
Tringale, K. R., Reiner, A. S., Sehgal, R. R., Panageas, K., Betof Warner, A. S., Postow, M. A., & Moss, N. S. (2023). Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure. CNS Oncology, 12(1), CNS93. -
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
Betof Warner, A., Tarhini, A., Kang, B., Nakasato, A., Ling, Y.-L. L., Shah, R., … Patel, J. (2023). Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients. Melanoma Research, 33(1), 38–49. -
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., … Tawbi, H. A. (2022). Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature, 611(7934), 155–160. -
Inflammatory vulvar dermatoses following immune checkpoint inhibitor therapy.
Sia, T. Y., Warner, A. B., Noor, S. J., Aviki, E. M., & Long Roche, K. (2022). Inflammatory vulvar dermatoses following immune checkpoint inhibitor therapy. American Journal of Obstetrics and Gynecology. -
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
Yang, J. T., Wijetunga, N. A., Pentsova, E., Wolden, S., Young, R. J., Correa, D., … Boire, A. (2022). Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(33), 3858–3867. -
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Bai, X., Shoushtari, A. N., Betof Warner, A., Si, L., Tang, B., Cui, C., … Guo, J. (2022). Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. The British Journal of Dermatology, 187(3), 401–410. -
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Postow, M. A., Goldman, D. A., Shoushtari, A. N., Betof Warner, A., Callahan, M. K., Momtaz, P., … Chapman, P. B. (2022). Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(10), 1059–1067. -
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis.
Wijetunga, N. A., Boire, A., Young, R. J., Yamada, Y., Wolden, S., Yu, H., … Yang, J. T. (2021). Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. Neuro-Oncology Advances, 3(1), vdab181. -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman, P. B., Jayaprakasam, V. S., Panageas, K. S., Callahan, M., Postow, M. A., Shoushtari, A. N., … Betof Warner, A. (2021). Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. Journal for Immunotherapy of Cancer, 9(10). -
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle, B. R., Betof Warner, A., Zaman, F. Y., Haydon, A., Bhave, P., Dewan, A. K., … Rotemberg, V. M. (2021). Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. Journal for Immunotherapy of Cancer, 9(10). -
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Hirschhorn, D., Betof Warner, A., Maniyar, R., Chow, A., Mangarin, L. M., Cohen, A. D., … Wolchok, J. D. (2021). Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight, 6(20). -
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Shen, R., Postow, M. A., Adamow, M., Arora, A., Hannum, M., Maher, C., … Callahan, M. K. (2021). LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 13(608). -
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Bai, X., Hu, J., Betof Warner, A., Quach, H. T., Cann, C. G., Zhang, M. Z., … Boland, G. M. (2021). Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 27(21), 5993–6000. -
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva, I., Ahmed, T., Reijers, I. L., Weppler, A. M., Betof Warner, A., Patrinely, J. R., … Long, G. V. (2021). Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. The Lancet. Oncology, 22(6), 836–847. -
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Shoushtari, A. N., Chatila, W. K., Arora, A., Sanchez-Vega, F., Kantheti, H. S., Rojas Zamalloa, J. A., … Schultz, N. (2021). Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 27(8), 2226–2235. -
Dermatologic infections in cancer patients treated with checkpoint inhibitors.
Do, M. H., Barrios, D. M., Phillips, G. S., Postow, M. A., Warner, A. B., Rosenberg, J. E., … Lacouture, M. E. (2021). Dermatologic infections in cancer patients treated with checkpoint inhibitors. Journal of the American Academy of Dermatology, 85(6), 1528–1536. -
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
Beattie, J., Rizvi, H., Fuentes, P., Luo, J., Schoenfeld, A., Lin, I.-H. H., … Hellmann, M. D. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for Immunotherapy of Cancer, 9(2). -
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Betof Warner, A., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., … Chapman, P. B. (2020). Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 38(15), 1655–1663. -
Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.
Tokunaga, A., Sugiyama, D., Maeda, Y., Warner, A. B., Panageas, K. S., Ito, S., … Nishikawa, H. (2019). Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. The Journal of Experimental Medicine, 216(12), 2701–2713. -
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner, S., Kwong, E., Shoushtari, A. N., Friedman, C. F., Betof, A. S., Brady, M. S., … Postow, M. A. (2018). Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Medicine, 7(3), 690–697. -
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., … Shoushtari, A. N. (2018). Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29(1), 250–255. -
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
Betof, A. S., Nipp, R. D., Giobbie-Hurder, A., Johnpulle, R. A., Rubin, K., Rubinstein, S. M., … Sullivan, R. J. (2017). Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. The Oncologist, 22(8), 963–971. -
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.
Betof, A. S., Lascola, C. D., Weitzel, D., Landon, C., Scarbrough, P. M., Devi, G. R., … Dewhirst, M. W. (2015). Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. Journal of the National Cancer Institute, 107(5). -
Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer.
Jones, L. W., Antonelli, J., Masko, E. M., Broadwater, G., Lascola, C. D., Fels, D., … Freedland, S. J. (2012). Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. Journal of Applied Physiology (Bethesda, Md. : 1985), 113(2), 263–72. -
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
Betof, A. S., Rabbani, Z. N., Hardee, M. E., Kim, S. J., Broadwater, G., Bentley, R. C., … Blackwell, K. L. (2012). Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. British Journal of Cancer, 106(5), 916–22. -
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.
Vujaskovic, Z., Kim, D. W., Jones, E., Lan, L., McCall, L., Dewhirst, M. W., … Blackwell, K. (2010). A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 26(5), 514–21. -
Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor, T. D., Hanna, G., Yarmolenko, P. S., Dreher, M. R., Betof, A. S., Nixon, A. B., … Dewhirst, M. W. (2010). Effect of pazopanib on tumor microenvironment and liposome delivery. Molecular Cancer Therapeutics, 9(6), 1798–808. -
Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View.
Betof-Warner, A., Sullivan, R. J., & Sarnaik, A. (2022). Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 42, 1–8. -
Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022)
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., … Tawbi, H. A. (2023). Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022). NATURE, E23. -
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
Atkinson, T. M., Hay, J. L., Young Kim, S., Schofield, E., Postow, M. A., Momtaz, P., … Chapman, P. B. (2023). Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. ONCOLOGIST. -
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply
da Silva, I. P., Ahmed, T., Reijers, I. L. M., Warner, A. B., Patrinely, J. R., Serra-Bellver, P., … Long, G. (2021). Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply. LANCET ONCOLOGY, 22(8), E343–E344. -
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon
Betof Warner, A., & Postow, M. A. (2020). Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon. JOURNAL OF CLINICAL ONCOLOGY, 38(6), 529-+. -
Exercise as Adjunct Therapy in Cancer
Ashcraft, K. A., Warner, A. B., Jones, L. W., & Dewhirst, M. W. (2019). Exercise as Adjunct Therapy in Cancer. SEMINARS IN RADIATION ONCOLOGY, 29(1), 16–24. -
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma
Warner, A. B., & Postow, M. A. (2018). Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma. CLINICAL CANCER RESEARCH, 24(20), 4915–4917. -
The brim of uncertainty in adjuvant treatment of melanoma
Warner, A. B., & Postow, M. A. (2018). The brim of uncertainty in adjuvant treatment of melanoma. LANCET ONCOLOGY, 19(4), 436–437. -
End-of-Life Care for Patients with Potentially Resectable Pancreatic Cancer Who Received Radiation Therapy
Yerramilli, D., Betof, A., Drapek, L. C., Wo, J. Y., Hong, T. S., & Nipp, R. (2017). End-of-Life Care for Patients with Potentially Resectable Pancreatic Cancer Who Received Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data
Ashcraft, K. A., Peace, R. M., Betof, A. S., Dewhirst, M. W., & Jones, L. W. (2016). Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data. CANCER RESEARCH, 76(14), 4032–4050. -
Effects and potential mechanisms of exercise training on cancer progression: A translational perspective
Betof, A. S., Dewhirst, M. W., & Jones, L. W. (2013). Effects and potential mechanisms of exercise training on cancer progression: A translational perspective. BRAIN BEHAVIOR AND IMMUNITY, 30, S75–S87. -
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schröder, D., Chow, A., … Merghoub, T. (2023). T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell, 186(7), 1432–1447.e17. -
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Loo, K., Kalvin, H. L., Panageas, K. S., Callahan, M. K., Chapman, P. B., Momtaz, P., … Warner, A. B. (2023). Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1. Pigment Cell & Melanoma Research. -
Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy.
Lee, S., Bennett, A. V., Zhou, X., Betof Warner, A., Trogdon, J. G., Kent, E. E., & Lund, J. L. (2023). Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy. Pharmacoepidemiology and Drug Safety. -
Diversity, equity, and inclusion in the melanoma research community.
Portuallo, M. E., Lu, D. Y., Alicea, G. M., Bolling, J., Lee, R., McQuade, J., … Rebecca, V. W. (2023). Diversity, equity, and inclusion in the melanoma research community. Pigment Cell & Melanoma Research. -
Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study.
Augustin, R. C., Huang, Z., Ding, F., Zhai, S., McArdle, J., Santisi, A., … Najjar, Y. G. (2023). Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study. Frontiers in Oncology, 13, 1075823. -
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto, P. A., Agarwala, S. S., Warner, A. B., Ernstoff, M. S., Fox, B. A., Gajewski, T. F., … Thurin, M. (2023). Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). Journal of Translational Medicine, 21(1), 508. -
CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II.
Betof Warner, A., & Luke, J. J. (2023). CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions.
Betof Warner, A. (2023). Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions. Cancer Immunology Research, OF1. -
A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
Warner, A. B., Postow, M. A., Panageas, K., Smithy, J. W., Schoenfeld, A. J., Wolchok, J. D., & Shoushtari, A. N. (2023). A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers.
Malani, R., Bhatia, A., Warner, A. B., & Yang, J. T. (2023). Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers. Seminars in Neurology. -
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner, A., Versluis, J. M., Wallace, R., Allayous, C., Brown, L. J., Trojaniello, C., … Menzies, A. M. (2023). The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer (Oxford, England : 1990), 196, 113441. -
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Betof Warner, A., Hamid, O., Komanduri, K., Amaria, R., Butler, M. O., Haanen, J., … Schoenfeld, A. J. (2024). Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Journal for Immunotherapy of Cancer, 12(2). -
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen, S. T., Semenov, Y. R., Alloo, A., Bach, D. Q., Betof Warner, A., Bougrine, A., … LeBoeuf, N. R. (2024). Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. Journal for Immunotherapy of Cancer, 12(4). -
Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Smithy, J. W., Kalvin, H. L., Ehrich, F. D., Shah, R., Adamow, M., Raber, V., … Postow, M. A. (2024). Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
Haanen, J., Los, C., Phan, G. Q., & Betof Warner, A. (2024). Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 44(3), e431608. -
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab.
Lochrin, S. E., Buonocore, D. J., Young, R. J., Kaley, T. J., Postow, M. A., Wolchok, J. D., … Callahan, M. K. (2024). Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab. Pigment Cell & Melanoma Research. -
A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
Warner, A. B., Smithy, J. W., Postow, M. A., Panageas, K., Schoenfeld, A. J., Wolchok, J. D., & Shoushtari, A. N. (2024). A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment patterns with expert recommendations
Becker, M. N., Rosenthal, K. M., Warner, A. B., Daud, A., Lipson, E. J., Tarhini, A. A., & Tawbi, H. A. (2024). Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment patterns with expert recommendations. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
Schoenfeld, A. J., Warner, A. B., Chesney, J. A., Thomas, S. S., Hamid, O., In, G. K., … He, K. (2024). A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults.
Taparra, K., Kekumano, K., Benavente, R., Roberto, L., Gimmen, M., Shontell, R., … Pollom, E. (2024). Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults. JAMA Network Open, 7(8), e2430975. -
Trial in Progress: A Phase 1/2 Study to Investigate the Safety and Efficacy of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients (Pts) with Advanced Solid Tumors
Schoenfeld, A. J., Warner, A. B., Thomas, S. S., Hamid, O., In, G. K., Shoushtari, A. N., … Chesney, J. A. (2024). Trial in Progress: A Phase 1/2 Study to Investigate the Safety and Efficacy of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients (Pts) with Advanced Solid Tumors. MOLECULAR THERAPY. CELL PRESS. -
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.
Cesano, A., Augustin, R., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., … Marincola, F. M. (2025). Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review. Journal for Immunotherapy of Cancer, 13(1). -
Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.
Avutu, V., Algazaq, J. N., Seier, K., Desir-Camille, R., Qin, L.-X. X., Babatunde, O., … Seo, S. K. (2025). Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy. Transplantation and Cellular Therapy. -
The Clinical TIL Experience in Melanoma: Past, Present, Future.
Smithy, J. W., Schoenfeld, A. J., & Betof Warner, A. (2025). The Clinical TIL Experience in Melanoma: Past, Present, Future. Transplantation and Cellular Therapy, 31(3S), S626–S634. -
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Buchbinder, E., Lotze, M. T., Margolin, K. A., Amaria, R., Sarnaik, A., Seery, V., … Silk, A. W. (2025). Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. Journal for Immunotherapy of Cancer, 13(5). -
Proceedings of the seventh annual Women in Melanoma Conference
Najjar, Y. G., Orloff, M., Mitchell, T. C., Bowles, T. L., Betof Warner, A., Bollin, K., … Patel, S. P. (2025). Proceedings of the seventh annual Women in Melanoma Conference. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 17. -
Proceedings of the seventh annual Women in Melanoma Conference.
Najjar, Y. G., Orloff, M., Mitchell, T. C., Bowles, T. L., Betof Warner, A., Bollin, K., … Patel, S. P. (2025). Proceedings of the seventh annual Women in Melanoma Conference. Therapeutic Advances in Medical Oncology, 17, 17588359251342039. -
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
Pandit-Taskar, N., Mauguen, A., Frosina, D., Jungbluth, A., Busam, K. J., Lyashchenko, S., … Postow, M. A. (2025). Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study. Melanoma Research. -
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Burton, E. M., Milton, D. R., Tetzlaff, M. T., Wani, K., Ross, M. I., Postow, M. A., … Amaria, R. N. (2025). Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2500494. -
SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma.
Luke, J. J., Warner, A. B., Chmielowski, B., Diab, A., Gebhardt, C., Hernandez-Aya, L. F., … Britten, C. (2025). SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The multidisciplinary community of exercise oncology practice: current status and future directions.
Cao, C., Campbell, K. L., Warner, A. B., Campbell, N., Schwartz, A. L., Cleary, C., … Ligibel, J. A. (2025). The multidisciplinary community of exercise oncology practice: current status and future directions. Journal of the National Cancer Institute. Monographs, 2025(71), 344–350. -
History informing the future of exercise oncology.
Galvao, D. A., Courneya, K. S., Lucia, A., May, A. M., Mustian, K., Warner, A. B., … Newton, R. U. (2025). History informing the future of exercise oncology. Journal of the National Cancer Institute. Monographs, 2025(71), 306–314. -
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.
Yang, J. T., Yerramilli, D., Pentsova, E., Wolden, S., Young, R. J., Correa, D. D., … Boire, A. (2025). Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial. JAMA Oncology. -
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Zhu, L., Cheung, Y.-M. M., Chiang, C., Gallagher, E. J., Hamnvik, O.-P. R., Mammen, J., … Shariff, A. (2025). Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. Journal for Immunotherapy of Cancer, 13(10). -
Association between exercise and clinical outcomes in patients treated with immunotherapy for solid tumors.
Loo, K., Lavery, J. A., Palmer, J., Guo, W., Underwood, W. P., Moskowitz, C. S., … Betof, A. S. (2025). Association between exercise and clinical outcomes in patients treated with immunotherapy for solid tumors. Frontiers in Immunology, 16, 1694045. -
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
Da Silva, I. P., Ahmed, T., Lo, S., Reijers, I. L. M., Weppler, A., Warner, A. B., … Long, G. V. (2020). Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner, A. B., & Postow, M. A. (2018). Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma? ONCOLOGY-NEW YORK, 32(5), 228–234. -
Sleeve gastrectomy strictures: technique for robotic-assisted strictureplasty
Sudan, R., Kasotakis, G., Betof, A., & Wright, A. (2010). Sleeve gastrectomy strictures: technique for robotic-assisted strictureplasty. SURGERY FOR OBESITY AND RELATED DISEASES, 6(4), 434–436. -
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Alban, J., Bowen, R. C., Reichstein, D. A., McKean, M., Lutzky, J., Weis, E., … Chandra, S. (2025). Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus. Cancers, 18(1).
-
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- A Study to Investigate LYL845 in Adults With Solid Tumors
- Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
- Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
Practice Locations
Skin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Dr, 3rd Fl
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereStanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto Palo Alto, CA
Palo Alto, CA
Stanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto
900 Blake Wilbur Dr, 3rd Fl
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Review Summary
Dr. Betof Warner is regarded as caring, thoughtful, and thorough. Her communication is clear and easy to understand. She is known for her excellent doctor-patient skills and for being knowledgeable, taking the time to listen and answer questions. Patients feel they are in good hands and well cared for, and appreciate her kind demeanor.
The summary was created by AI, based on recent patient reviews. Learn more
Patient Reviews
(34 reviews)
We are from San Diego and were very happy to be able to get guidance from Dr. Betof Warner with all her experience in melanoma. She was very knowledgeable and helped us feel very comfortable with a major decision
Dr. Betoff was not feeling well, so the video visit was conducted from home. I appreciate her caring for her patients to the level she was willing and able to conduct this visit in that manner. She's thorough, very communicative, and personable.
First impression…. Absolutely LOVE HER
Dr. Betof is extremely knowledgable, informed, empathetic, conscientious, and compassionate.
Dr. Betof Warner is amazing! She has been very communication during the course of my treatment at Stanford. Her conversation style is open and direct. She is willing to listen to my questions and concerns, and answers them fully and in verbage that is not overly 'technical'.
I appreciate her and her staff for all the help, support, care, and advice during my treatment.
She is very compassionate and listens to your concerns. I would highly recommend her to anyone!
The entire staff was wonderful. They explained everything to me and I feel like I’m an excellent hands. I want to thank you very much.
I have nothing but the best things to say about all of the care I have received at Stanford Hospital. Every single person that I have encountered from the doctors to the people that greet you when you first enter in the buildings have been nothing but kind and helpful.
Excellent doctor-patient skill
All the staff were nice, but the DOCTOR was very caring and made me feel I was in GOOD hands!!
Outstanding health care. Outstanding physician.
Dr. Betof and her staff are amazing. Dr. Betof is so thoughtful and thorough in with my care.
I adore her!
Perfect doctor and team
so supportive, compassionate and thorough
Excellent doctor, very knowledgeble and very good bedside manner. She takes the time to listen, to understand questions and to give comprehensive well thought out answers.
Dr Betof is such a wonderful doctor. She is so caring and personable and of course so very smart. She put you completely Eddie’s whenever you are with her and Phil very well taken care of.
Dr. Warner’s kind demeanor and optimism made us feel more at ease.
Excellent physician and human being.
Alison Betof is superb.
She is forthcoming, extremely knowledgeable, able to communicate her diagnostic and clinical decisions clearly and accurately, and with care and compassion.
We think she is just the sweetest doctor! Not only that but she is so smart and on top of everything!
Very personable, easy to understand
She is amazing and an asset to Stanford. I am so grateful for her care. I have something wrong with me and no one has been able to figure it out at my primary insurance, but Dr. Betof Warner made excellent suggestions for my local oncologist to explore.
Appreciate her accepting my consult request.
The doctor and her staff are very informative and easy to talk to.
Dr. Betof is cheerful, and relaxed, and conveys concern regarding my health. I appreciate her schedule and know she is quite busy but she does not appear hurried or stressed. She takes as much time as necessary to listen to and answer my questions without my feeling rushed. I am confident in her expertise in treating me.
Very thankful that she is taking care of me!
I am a new patient of Dr. Betof and am impressed with her knowledge of my condition. She is personable, professional, and communicates very well. I am pleased she is my treating oncologist. Thank You.
I could tell from first video visit that I was lucky to have her as part of my team. She is friendly, warm and knows her stuff
The doctor has been great! Always answers all my questions.
The best!
Very professional and caring.
Dr Betof was amazing. She was extremely knowledgeable and the type of cancer I have she had a plan. She was very compassionate… Everything I needed from that visit she provided.
How could anyone not give Dr. Betof overall high ratings? She's personable, obviously knowledgeable, thorough, explained issues well, and followed through doing what she said she would do. Well done Dr. Betof!
Dr. Betof is outstanding. Being under her care and the care of her team is the best medical care I’ve ever been given.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records